摘要
目的观察吉非替尼(Gefitinib,ZD1839)作为一线化疗方案治疗老年非小细胞肺癌的效果及毒副作用。方法26例经病理学或细胞学检查确诊的老年非小细胞肺癌患者(≥60岁),应用吉非替尼(250mg,每日1次,口服)治疗直至病情进展或出现严重不良反应。结果26例可评价疗效,CR为3.8%(1/26),PR为34.6%(9/26),有效率为38.4%;SD为38.5%(10/26);疾病控制率为76.9%;PD为23.1%(6/26)。中位缓解时间为6.6个月,中位肿瘤进展时间为5.5个月,中位生存期为11.2个月,1年生存率为36.6%。疗效与患者性别、皮疹等因素有密切关系。与药物相关的不良反应依次为:皮疹、腹泻、恶心、关节痛、肝功能异常。尚无因不良反应需停药者。结论吉非替尼治疗疗效明确,毒副反应较轻,耐受性较好,可以明显改善患者生存质量,作为老年非小细胞肺癌的一线治疗药物值得推广。
Objective To observe the efficacy and drug-related toxicities of Gefitinib in the first-line treatment of elderly patients with non-small cell lung cancer.Methods 26 elderly patients with histologically or cytologically diagnosed non-small cell lung cancer were treated with gefitinib（at a dose of 250mg per day orally） until the disease progression or intolerable toxicities.Results All the 26 patients were evaluable.The overall response rate was 38.4%,including 3.8%（1/26） patients with complete response and 34.6%（8/26） patients with partial response.38.5%（10/26） patients had stable disease and 23.1%（6/26） patients had progressive disease,so the disease control rate is 76.9%.The median duration of response and the median time to disease progression（TTP） were 6.6 and 5.5 months,respectively.The median overall survival time（OS） was 11.2 months and the 1-year survival rate was 36.6%.Drug-related adverse reactions included skin rash,diarrhea,nausea,joint pain,liver injury.No patients stopped the treatment due to the toxicities.Conclusion Gefitinib is effective in the treatment of elderly patients with non small cell lung cancer.The toxicities are mild and tolerable.Treatment with Gefitinib could be considered as first-line therapy to elderly patients with non-small cell lung cancer.
出处
《实用癌症杂志》
2008年第4期402-405,共4页
The Practical Journal of Cancer
关键词
吉非替尼
靶向治疗
一线治疗
老年非小细胞肺癌
Gefitinib
Targeted therapy
First-line therapy
Elderly non-small cell lung cancer
